|Bid||7.08 x 900|
|Ask||7.12 x 1000|
|Day's range||6.70 - 7.46|
|52-week range||2.23 - 24.90|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||13.33|
Ocugen (NASDAQ: OCGN) and Vaxart (NASDAQ: VXRT) stand out as two small companies hoping to achieve success. Vaxart's shares skyrocketed more than 1,500% in 2020, but Ocugen has been the bigger winner so far this year. Ocugen actually hasn't developed a COVID-19 vaccine candidate.
On Wednesday, the Biden administration backed waiving intellectual property protections for COVID-19 vaccines, a move that delighted Sen. Elizabeth Warren.
Vaxart (NASDAQ: VXRT) is betting that, yes, people will prefer to avoid the pain of a jab if they have the option of taking its oral-pill vaccines. Now that there are a plethora of other coronavirus vaccines that are already approved for sale and actively gaining market share, can Vaxart still deliver for its investors? According to a (questionably rigorous) survey that Vaxart commissioned recently, 32% of the people in the U.S. who are not currently intending to get vaccinated for COVID-19 would be likely to do so if they could take a pill instead of getting an injection.